Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Effects of CYP2C19 and CYP2C9 genetic polymorphisms on the disposition of and blood glucose lowering response to tolbutamide in humans.

Pharmacogenetics - 1 Mar 2002

Shon Ji-Hong, Yoon Young-Ran, Kim Kyoung-Ah, Lim Young-Chae, Lee Kwang-Jae, Park Ji-Young, Cha In-June, Flockhart David A, Shin Jae-Gook

Abstract excerpt

Several recent in-vitro data have revealed that CYP2C19, in addition to CYP2C9, is also involved in the 4-methylhydroxylation of tolbutamide. We evaluated the relative contribution of CYP2C9 and CYP2C19 genetic polymorphisms on the disposition of blood glucose lowering response to tolbutamide in normal healthy Korean subjects in order to reappraise tolbutamide as a selective in-vivo probe substrate of CYP2C9...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Area Under Curve
Share to Cross-Over Studies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP2C9

Share to Hydroxylation

Share to Hypoglycemic Agents

Share to Single-Blind Method

Share to Steroid 16-alpha-Hydroxylase

Share to Steroid Hydroxylases

Source

Identifiers

PMID: 11875365
DOI: 10.1097/00008571-200203000-00005

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Effects of CYP2C19 and CYP2C9 genetic polymorphisms on the disposition of and blood glucose lowering response to tolbutamide in humans.PMID 11875365Read ↗

Impact of CYP2C9 and CYP2C19 polymorphisms on tolbutamide kinetics and the insulin and glucose response in healthy volunteers.Semantic proximity Read ↗

Relationship of P450 2C9 genetic polymorphisms in Chinese and the pharmacokinetics of tolbutamide.Semantic proximity Read ↗

Evaluation of cytochrome P4502C9 metabolic activity with tolbutamide in CYP2C91 heterozygotes.Semantic proximity Read ↗

Cytochrome P450 2C9 phenotyping using low-dose tolbutamide.Semantic proximity Read ↗

Tolbutamide, flurbiprofen, and losartan as probes of CYP2C9 activity in humans.Semantic proximity Read ↗

The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism.Semantic proximity Read ↗

In vitro and in vivo characterization of 13 CYP2C9 allelic variants found in Chinese Han population.Semantic proximity Read ↗

CYP2C9 polymorphism: impact on tolbutamide pharmacokinetics and response.Semantic proximity Read ↗

Efavirenz and CYP2C9 Genetic Polymorphisms Reduce CYP2C9 Activity in Healthy Participants.Semantic proximity Read ↗

Relative impact of genotype and enzyme induction on the metabolic capacity of CYP2C9 in healthy volunteers.Semantic proximity Read ↗

Phenotypic analysis of human CYP2C9 polymorphisms using fluorine-substituted tolbutamide.Semantic proximity Read ↗

Estimation of Interindividual Variability of Pharmacokinetics of CYP2C9 Substrates in Humans.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.